Related Experiment Video

Updated: May 11, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

Andrew M Intlekofer1, Craig B Thompson

  • 1Department of Medicine, Cancer Biology and Genetics Program, and Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Journal of Leukocyte Biology
|April 30, 2013
PubMed

Insights

Blocking immune checkpoints like CTLA-4 and PD-1 can enhance anti-tumor immunity. Combined blockade of both receptors may offer more potent cancer immunotherapy by overcoming tumor evasion strategies.

Area of Science:

  • Immunology
  • Oncology
  • Cancer immunotherapy

Background:

  • Tumors evade immune surveillance by activating immune inhibitory receptors.
  • Immune checkpoints, such as CTLA-4 and PD-1, suppress T cell responses against cancer.
  • Targeting these checkpoints offers a strategy to enhance anti-tumor immunity.

Purpose of the Study:

  • To investigate the potential of blocking immune inhibitory checkpoints for cancer immunotherapy.
  • To explore the independent and combined effects of CTLA-4 and PD-1 blockade on anti-tumor immunity.

Main Methods:

  • Preclinical investigations of T cell-inhibitory receptors CTLA-4 and PD-1.
  • Analysis of the mechanisms and sites of action for CTLA-4 and PD-1.
  • Evaluation of therapeutic blockade strategies for these immune checkpoints.

Main Results:

  • CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4) regulates T cell activation thresholds and proliferation.
  • PD-1 (Programmed cell death protein 1) limits T cell effector function within the tumor microenvironment.
  • Blocking either CTLA-4 or PD-1 can promote anti-tumor immune responses.

Conclusions:

  • Therapeutic blockade of immune checkpoints is a promising approach for cancer immunotherapy.
  • Combined blockade of CTLA-4 and PD-1 may yield more potent anti-tumor activity than monotherapy.
  • Understanding the distinct roles of CTLA-4 and PD-1 informs combination strategies for improved cancer treatment.
Keywords:
PD-L1coinhibitorycostimulationcostimulatoryinhibitoryipilimumabreceptortumor

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...